Virginia Kan
Overview
Explore the profile of Virginia Kan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, et al.
J Infect Dis
. 2024 Sep;
PMID: 39269490
Background: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests....
2.
Zucco A, Bennedbaek M, Ekenberg C, Gabrielaite M, Leung P, Polizzotto M, et al.
AIDS
. 2023 Aug;
37(11):1643-1650.
PMID: 37534724
Objective: Human leucocyte antigen (HLA) class I alleles are the main host genetic factors involved in controlling HIV-1 viral load (VL). Nevertheless, HLA diversity has proven a significant challenge in...
3.
Brown S, Barkauskas C, Grund B, Sharma S, Phillips A, Leither L, et al.
Lancet Respir Med
. 2023 Jun;
11(9):791-803.
PMID: 37348524
Background: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide...
4.
Gabrielaite M, Bennedbaek M, Rasmussen M, Kan V, Furrer H, Flisiak R, et al.
PLoS Comput Biol
. 2023 Jan;
19(1):e1010756.
PMID: 36595537
Background: Infection with human immunodeficiency virus type 1 (HIV) typically results from transmission of a small and genetically uniform viral population. Following transmission, the virus population becomes more diverse because...
5.
Rogers A, Wentworth D, Phillips A, Shaw-Saliba K, Dewar R, Aggarwal N, et al.
Ann Intern Med
. 2022 Aug;
175(10):1401-1410.
PMID: 36037469
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19. Objective: To evaluate whether...
6.
Barkauskas C, Mylonakis E, Poulakou G, Young B, Vock D, Siegel L, et al.
Ann Intern Med
. 2022 Aug;
175(9):1266-1274.
PMID: 35939810
Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. Objective: To investigate if ensovibep, in addition...
7.
Douin D, Siegel L, Grandits G, Phillips A, Aggarwal N, Baker J, et al.
Am J Respir Crit Care Med
. 2022 May;
206(6):730-739.
PMID: 35580040
Uncertainty regarding the natural history of coronavirus disease (COVID-19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur after hospital discharge may improve assessment of...
8.
Brown S, Peltan I, Barkauskas C, Rogers A, Kan V, Gelijns A, et al.
Ann Am Thorac Soc
. 2021 Jul;
18(12):1948-1950.
PMID: 34288834
No abstract available.
9.
Wendt C, Castro-Pearson S, Proper J, Pett S, Griffin T, Kan V, et al.
PLoS One
. 2021 Apr;
16(4):e0247493.
PMID: 33798209
Background: We performed metabolomic profiling to identify metabolites that correlate with disease progression and death. Methods: We performed a study of adults hospitalized with Influenza A(H1N1)pdm09. Cases (n = 32)...
10.
Ekenberg C, Reekie J, Zucco A, Murray D, Sharma S, MacPherson C, et al.
AIDS
. 2021 Feb;
35(5):783-789.
PMID: 33587436
Objectives: The Strategic Timing of AntiRetroviral Treatment (START) and Strategies for Management of Antiretroviral Therapy (SMART) trials demonstrated that ART can partly reverse clinically defined immune dysfunction induced by HIV...